Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.05
MNK's Cash to Debt is ranked lower than
95% of the 779 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. MNK: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
MNK' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.24 Max: N/A
Current: 0.05
Equity to Asset 0.34
MNK's Equity to Asset is ranked lower than
86% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MNK: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
MNK' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.35 Max: 0.39
Current: 0.34
0.32
0.39
Interest Coverage 1.61
MNK's Interest Coverage is ranked lower than
93% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.94 vs. MNK: 1.61 )
Ranked among companies with meaningful Interest Coverage only.
MNK' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 2.69 Max: 470.4
Current: 1.61
0.53
470.4
F-Score: 6
Z-Score: 0.75
M-Score: -2.63
WACC vs ROIC
13.43%
6.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 18.26
MNK's Operating margin (%) is ranked higher than
77% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.61 vs. MNK: 18.26 )
Ranked among companies with meaningful Operating margin (%) only.
MNK' s Operating margin (%) Range Over the Past 10 Years
Min: 2.63  Med: 11.68 Max: 18.26
Current: 18.26
2.63
18.26
Net-margin (%) 19.04
MNK's Net-margin (%) is ranked higher than
85% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. MNK: 19.04 )
Ranked among companies with meaningful Net-margin (%) only.
MNK' s Net-margin (%) Range Over the Past 10 Years
Min: -19.35  Med: 7 Max: 19.04
Current: 19.04
-19.35
19.04
ROE (%) 12.34
MNK's ROE (%) is ranked higher than
68% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MNK: 12.34 )
Ranked among companies with meaningful ROE (%) only.
MNK' s ROE (%) Range Over the Past 10 Years
Min: -10.28  Med: 7.85 Max: 12.34
Current: 12.34
-10.28
12.34
ROA (%) 4.04
MNK's ROA (%) is ranked higher than
53% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. MNK: 4.04 )
Ranked among companies with meaningful ROA (%) only.
MNK' s ROA (%) Range Over the Past 10 Years
Min: -3.91  Med: 2.77 Max: 4.04
Current: 4.04
-3.91
4.04
ROC (Joel Greenblatt) (%) 49.93
MNK's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.31 vs. MNK: 49.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 3.34  Med: 18.27 Max: 50.3
Current: 49.93
3.34
50.3
Revenue Growth (3Y)(%) 0.80
MNK's Revenue Growth (3Y)(%) is ranked lower than
64% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. MNK: 0.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MNK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.2  Med: -10.1 Max: 0.8
Current: 0.8
-11.2
0.8
EBITDA Growth (3Y)(%) 51.90
MNK's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. MNK: 51.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.5  Med: 11.5 Max: 51.9
Current: 51.9
-7.5
51.9
GuruFocus has detected 2 Warning Signs with Mallinckrodt PLC $MNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNK's 10-Y Financials

Financials (Next Earnings Date: 2017-02-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MNK Guru Trades in Q4 2015

George Soros 6,500 sh (New)
Paul Tudor Jones 8,097 sh (New)
Mario Gabelli 15,562 sh (New)
Louis Moore Bacon 16,998 sh (New)
David Dreman 203 sh (New)
Ken Heebner 665,000 sh (New)
Jeremy Grantham 3,834 sh (New)
John Paulson 8,623,693 sh (+30.78%)
First Eagle Investment 187 sh (unchged)
Steven Cohen Sold Out
John Hussman Sold Out
Andreas Halvorsen Sold Out
Jim Simons Sold Out
Pioneer Investments Sold Out
Joel Greenblatt Sold Out
» More
Q1 2016

MNK Guru Trades in Q1 2016

Joel Greenblatt 580,887 sh (New)
David Dreman 4,027 sh (+1883.74%)
Ken Heebner 1,125,000 sh (+69.17%)
John Paulson 8,949,380 sh (+3.78%)
First Eagle Investment 187 sh (unchged)
George Soros Sold Out
Jeremy Grantham Sold Out
Louis Moore Bacon Sold Out
Paul Tudor Jones 7,622 sh (-5.87%)
Mario Gabelli 14,562 sh (-6.43%)
» More
Q2 2016

MNK Guru Trades in Q2 2016

Steven Cohen 120,400 sh (New)
David Dreman 4,448 sh (+10.45%)
Mario Gabelli 14,562 sh (unchged)
First Eagle Investment 187 sh (unchged)
John Paulson 8,371,080 sh (-6.46%)
Ken Heebner 1,014,000 sh (-9.87%)
Paul Tudor Jones 5,434 sh (-28.71%)
Joel Greenblatt 246,825 sh (-57.51%)
» More
Q3 2016

MNK Guru Trades in Q3 2016

Jim Simons 207,102 sh (New)
Paul Tudor Jones 7,336 sh (+35.00%)
Joel Greenblatt 327,572 sh (+32.71%)
First Eagle Investment 187 sh (unchged)
David Dreman 4,448 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 14,462 sh (-0.69%)
John Paulson 7,974,472 sh (-4.74%)
Ken Heebner 880,500 sh (-13.17%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX, OTCPK:HKMPF, NAS:OPK, OTCPK:HYPMY, NYSE:TARO, OTCPK:IPSEY, NYSE:PTHN, NAS:NBIX, NYSE:RDY, NYSE:CTLT, OTCPK:HLUKF, OTCPK:SFOSF, NAS:ENDP, NAS:AKRX, NAS:HZNP, OTCPK:IZQVF, NAS:MDCO, OTCPK:SHPHF, NAS:IRWD, NAS:RDUS » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents.

Mallinckrodt PLC was incorporated in Ireland on January 9, 2013. The Company along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents. Its therapeutic areas of focus include autoimmune and rare disease specialty areas (including neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; pain management; and central nervous system drugs. It also supports the diagnosis of disease with nuclear medicine imaging agents. The Company operates in three segments including Specialty Brands, Specialty Generics, and Nuclear Imaging. Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals products for autoimmune and rare diseases (including in the specialty areas of neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; and central nervous system drugs. Its Specialty Brands product portfolio includes Acthar an injectable biopharmaceutical drug; Ofirmev a proprietary intravenous formulation of acetaminophen indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever; Inomax a vasodilator that, in conjunction with ventilatory support and other appropriate agents, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension; Therakos immunotherapy provides immunotherapy treatment platforms that enhance the ability of a patient's immune system to fight disease; and Exalgo a long-acting, once-daily form of hydromorphone. Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Specialty Generics product portfolio includes hydrocodone (API) and hydrocodone-containing tablets; hydrocodone (API) and hydrocodone-containing tablets; methylphenidate HCl extended-release tablets USP (CII); and other controlled substances, including acetaminophen (API) products. Nuclear Imaging segment develops, manufactures and markets products which provide radiopharmaceuticals used in single photon emission computed tomography ("SPECT") imaging for myocardial perfusion, cardiac imaging and bone scans. Its Nuclear Imaging business manufactures radioactive isotopes for the diagnosis and treatment of disease. Its nuclear radiopharmaceutical product offering includes both hot radioisotopes and cold kits. The Nuclear Imaging product portfolio includes Ultra-Technekow DTE a dry-ship, top

Ratios

vs
industry
vs
history
P/E(ttm) 8.05
MNK's P/E(ttm) is ranked higher than
92% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. MNK: 8.05 )
Ranked among companies with meaningful P/E(ttm) only.
MNK' s P/E(ttm) Range Over the Past 10 Years
Min: 7.84  Med: 24.74 Max: 73.31
Current: 8.05
7.84
73.31
Forward P/E 6.54
MNK's Forward P/E is ranked higher than
93% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.95 vs. MNK: 6.54 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.55
MNK's PE(NRI) is ranked higher than
87% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. MNK: 10.55 )
Ranked among companies with meaningful PE(NRI) only.
MNK' s PE(NRI) Range Over the Past 10 Years
Min: 10.28  Med: 48.61 Max: 3311.75
Current: 10.55
10.28
3311.75
P/B 0.94
MNK's P/B is ranked higher than
86% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. MNK: 0.94 )
Ranked among companies with meaningful P/B only.
MNK' s P/B Range Over the Past 10 Years
Min: 0.92  Med: 2.12 Max: 3.59
Current: 0.94
0.92
3.59
P/S 1.52
MNK's P/S is ranked higher than
68% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.91 vs. MNK: 1.52 )
Ranked among companies with meaningful P/S only.
MNK' s P/S Range Over the Past 10 Years
Min: 1.11  Med: 2.44 Max: 6.47
Current: 1.52
1.11
6.47
PFCF 5.22
MNK's PFCF is ranked higher than
94% of the 200 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.43 vs. MNK: 5.22 )
Ranked among companies with meaningful PFCF only.
MNK' s PFCF Range Over the Past 10 Years
Min: 5.08  Med: 18.2 Max: 2102.65
Current: 5.22
5.08
2102.65
POCF 4.39
MNK's POCF is ranked higher than
91% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.46 vs. MNK: 4.39 )
Ranked among companies with meaningful POCF only.
MNK' s POCF Range Over the Past 10 Years
Min: 4.28  Med: 13.94 Max: 45.78
Current: 4.39
4.28
45.78
EV-to-EBIT 17.27
MNK's EV-to-EBIT is ranked higher than
58% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.56 vs. MNK: 17.27 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s EV-to-EBIT Range Over the Past 10 Years
Min: 17.07  Med: 41.6 Max: 192.1
Current: 17.27
17.07
192.1
EV-to-EBITDA 7.36
MNK's EV-to-EBITDA is ranked higher than
86% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.22 vs. MNK: 7.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.28  Med: 15.2 Max: 34
Current: 7.36
7.28
34
PEG 0.76
MNK's PEG is ranked higher than
81% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.91 vs. MNK: 0.76 )
Ranked among companies with meaningful PEG only.
MNK' s PEG Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9965.8
Current: 0.76
0
9965.8
Current Ratio 1.22
MNK's Current Ratio is ranked lower than
80% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. MNK: 1.22 )
Ranked among companies with meaningful Current Ratio only.
MNK' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.14 Max: 2.31
Current: 1.22
1.22
2.31
Quick Ratio 0.95
MNK's Quick Ratio is ranked lower than
78% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. MNK: 0.95 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.67 Max: 1.95
Current: 0.95
0.95
1.95
Days Inventory 77.38
MNK's Days Inventory is ranked higher than
72% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. MNK: 77.38 )
Ranked among companies with meaningful Days Inventory only.
MNK' s Days Inventory Range Over the Past 10 Years
Min: 71.49  Med: 81.23 Max: 169.11
Current: 77.38
71.49
169.11
Days Sales Outstanding 50.29
MNK's Days Sales Outstanding is ranked higher than
73% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.25 vs. MNK: 50.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.29  Med: 73.29 Max: 105.41
Current: 50.29
50.29
105.41
Days Payable 26.34
MNK's Days Payable is ranked lower than
87% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.85 vs. MNK: 26.34 )
Ranked among companies with meaningful Days Payable only.
MNK' s Days Payable Range Over the Past 10 Years
Min: 26.34  Med: 41.19 Max: 52.77
Current: 26.34
26.34
52.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.90
MNK's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 429 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. MNK: -22.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.3  Med: -26.2 Max: -22.9
Current: -22.9
-26.3
-22.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.63
MNK's Price/Median PS Value is ranked higher than
86% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MNK: 0.63 )
Ranked among companies with meaningful Price/Median PS Value only.
MNK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.61  Med: 1 Max: 1.31
Current: 0.63
0.61
1.31
Earnings Yield (Greenblatt) (%) 5.82
MNK's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MNK: 5.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 2.4 Max: 5.89
Current: 5.82
0.5
5.89

More Statistics

Revenue (TTM) (Mil) $3,381
EPS (TTM) $ 5.77
Beta1.59
Short Percentage of Float9.29%
52-Week Range $45.32 - 85.83
Shares Outstanding (Mil)105.86

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 3,363 3,441 3,583
EPS ($) 7.51 8.52 9.34
EPS w/o NRI ($) 7.51 8.52 9.34
EPS Growth Rate
(3Y to 5Y Estimate)
6.00%
Dividends Per Share ($)
» More Articles for MNK

Headlines

Articles On GuruFocus.com
David Einhorn Converses on Range of Topics, Stocks With New York Times Editor Oct 20 2016 
10 Stocks David Dreman Is Buying Sep 21 2016 
Swiss Generics Manufacturer Has Strong 1st Half of Year Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
John Paulson Keeps Gold, Buys Drug Manufacturers Nov 17 2015 
Pioneer Investments Adds to Stakes in Hartford Financial Group, Reynolds American Nov 13 2015 
Andreas Halvorsen Buys AIG, Google, 3 More as Top New Stocks May 29 2015 
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 

More From Other Websites
[$$] Mallinckrodt Settles Antitrust Allegations on Unlawful Drug Monopoly Jan 18 2017
Drug firm to pay $100M to settle charges linked to Martin Shkreli-backed lawsuit Jan 18 2017
Mallinckrodt to pay $100 million to settle U.S. probe on drug pricing Jan 18 2017
Mallinckrodt to pay $100 million to settle U.S. probe on drug pricing Jan 18 2017
Mallinckrodt to pay $100 mln to settle U.S. probe on drug pricing Jan 18 2017
The Biggest Loser: Mallinckrodt Slumps 5.8% Jan 18 2017
Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug Jan 18 2017
Mallinckrodt And Federal Trade Commission Resolve Questcor Matter Jan 18 2017
Mallinckrodt Dives, Rebounds, Retreats On FTC Drug Price Settlement Jan 18 2017
Macy’s, DryShips Slide into Wednesday’s 52-Week Low Club Jan 18 2017
Why Mallinckrodt is Crumbling Jan 18 2017
Mallinkrodt Shares Tank Despite $100 Million FTC Deal Jan 18 2017
FTC, states settle with Mallinckrodt over Acthar Jan 18 2017
Mallinckrodt says it has settled with the FTC over allegedly using its monopoly to hike drug prices Jan 18 2017
Mallinckrodt erases losses, says they settled with FTC Jan 18 2017
3:11 pm Mallinckrodt responds to media reports regarding the previously disclosed FTC investigation,... Jan 18 2017
Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC Investigation Jan 18 2017
FTC set to file suit against Mallinckrodt for using monopoly to jack up drug prices Jan 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)